ExeVir Bio BV
ExeVir is a clinical stage biotech company dedicated to developing novel antibody therapies to prevent and treat infectious diseases, with a focus on protecting immunocompromised populations. They utilize a unique modular VHH platform to create multi-specific, stable, and cost-effective therapeutics capable of addressing current and emerging public health threats. Their pipeline includes therapies targeting COVID-19, dengue, and other infectious diseases, aiming to respond rapidly to outbreaks and unmet medical needs.
Industries
Nr. of Employees
small (1-50)
ExeVir Bio BV
VIB Bio-Incubator, Technologiepark-Zwijnaarde 94, 9052 Ghent, Belgium
Products
Multispecific antibody construct targeting SARS-CoV-2 S2 epitope
Bivalent single-domain construct that binds a conserved epitope in the S2 region of the SARS-CoV-2 spike to provide broad neutralization.
Multispecific antibody constructs targeting SARS-CoV-2 S1 region and combination cocktails
Bivalent/bispecific constructs targeting S1-region epitopes and combination products that combine constructs to target multiple epitopes and reduce immune escape.
Lead clinical-stage single-domain antibody candidate (early clinical data reported)
Lead antibody candidate progressed from research to clinical in under one year and completed Phase 1a and Phase 1b studies with reported favorable pharmacodynamics and manufacturability.
Pan-serotype dengue-targeting antibody construct
Antibody construct with a mode of action targeting all four dengue virus serotypes with potential cross-reactivity against other flaviviruses.
Multispecific antibody construct targeting SARS-CoV-2 S2 epitope
Bivalent single-domain construct that binds a conserved epitope in the S2 region of the SARS-CoV-2 spike to provide broad neutralization.
Multispecific antibody constructs targeting SARS-CoV-2 S1 region and combination cocktails
Bivalent/bispecific constructs targeting S1-region epitopes and combination products that combine constructs to target multiple epitopes and reduce immune escape.
Lead clinical-stage single-domain antibody candidate (early clinical data reported)
Lead antibody candidate progressed from research to clinical in under one year and completed Phase 1a and Phase 1b studies with reported favorable pharmacodynamics and manufacturability.
Pan-serotype dengue-targeting antibody construct
Antibody construct with a mode of action targeting all four dengue virus serotypes with potential cross-reactivity against other flaviviruses.
Services
Collaborative research and development partnerships to advance single-domain antibody programs through discovery and preclinical development up to IND readiness.
Partnerships with contract manufacturers to support GMP production, fill-and-finish, and scale-up for antibody therapeutics.
Execution of early-phase clinical studies including rapid translation from research to Phase 1 and Phase 1b/2 studies.
Collaborative research and development partnerships to advance single-domain antibody programs through discovery and preclinical development up to IND readiness.
Partnerships with contract manufacturers to support GMP production, fill-and-finish, and scale-up for antibody therapeutics.
Execution of early-phase clinical studies including rapid translation from research to Phase 1 and Phase 1b/2 studies.
Expertise Areas
- Antibody discovery and engineering (single-domain VHH)
- Multispecific biologics design
- Infectious disease therapeutics
- Preclinical efficacy and in vivo models
Key Technologies
- Single-domain (VHH) antibodies
- Multispecific/multivalent antibody constructs
- Fc-fusion protein engineering
- CHO mammalian cell expression
News & Updates
Poster presented by Florence Herschke at ID Week 2024, October 16-19, 2024, Los Angeles, USA
Presentation of promising data on XVR013m at ID Week 2024 in October 2024.
Announcement of high neutralization potency of XVR013m against SARS-CoV-2 variant JN.1 in June 2024.
Reporting positive neutralization data for XVR012 against Omicron variants in April 2024.
Announcement of EUR 25 million financing to advance XVR012 into clinical trials for COVID-19 in January 2024.
ExeVir is developing antibody therapeutics against emerging viral threats, with Michael Garrett appointed as CEO in November 2024.
Poster presented by Florence Herschke at ID Week 2024, October 16-19, 2024, Los Angeles, USA
Presentation of promising data on XVR013m at ID Week 2024 in October 2024.
Announcement of high neutralization potency of XVR013m against SARS-CoV-2 variant JN.1 in June 2024.
Reporting positive neutralization data for XVR012 against Omicron variants in April 2024.
Announcement of EUR 25 million financing to advance XVR012 into clinical trials for COVID-19 in January 2024.
ExeVir is developing antibody therapeutics against emerging viral threats, with Michael Garrett appointed as CEO in November 2024.